We performed a randomized trial comparing two dosing regimens of recombinant tissue plasminogen activator (rt-PA) plus heparin vs heparin alone in the treatment of acute proximal deep vein thrombosis in 83 patients. Of 12 patients who received 0.5 mgkg rt-PA plus heparin over 4 h, seven (58 percent) had greater than 50 percent lysis of the thrombus, compared with none of 12 who received placebo plus heparin (p=0.002). Of 28 patients who received 0.5 mgkg rt-PA over 8 h, repeated in 24 h, six (21 percent) had greater than 50 percent lysis, compared with two (7 percent) of 30 patients who received placebo plus heparin (p = 0.11).
The 4-h infusion of &-PA produced a 40 percent reduction and the 8-h infusion an 11 percent reduction in plasma fibrinogen concentration. At long-term follow-up, three (25 percent) of 12 patients in whom greater than 50 percent lysis was achieved had symptoms of the postphlebitic syndrome, compared with 19 (56 percent) of 34 patients in whom lysis was less than 50 percent (p = 0.07).
nticoagulant therapy is the standard treatment for A patients d t h venous thrombosis; it is used in over 90 percent of such patients treated in North America. Anticoagulant therapy is highly effective in preventing thrombus extension or embolization but does not produce significant thrombolysis,' and its use is associated with an appreciable rate of the postphlebitic syndrome. Thus, as many as two thirds ofpatients with deep vein thrombosis (DVT) who are treated with heparin experience loss of venous valve function and alteration of venous return, and more than half of all patients with proximal vein thrombosis develop symptoms of chronic venous insuffi~iency.'~~ Thrombolytic therapy induces lysis of thrombi and therefore has the potential to prevent venous valve damage and reduce the incidence of the postphlebitic syndrome. Although streptokinase (SK) and urokinase have been approved for the treatment of DVT for almost 20 years, heparin has remained the mainstay of acute therapy, mainly because of concern about hemorrhage with thrombolytic agents and uncertainty as to their effectiveness in preventing the postphlebitic syndrome. Streptokinase therapy has been evaluated in a number of small studies in patients with DVT and has been shown to produce greater lysis of thrombi than heparin when findings on repeat venography are used as the primary outcome m e a s~r e .~-~ A pooled analysis1° of the six randomized trials indicated that in patients treated with SK, significant lysis was achieved 3.7 times more often than patients treated with heparin, but with a threefold increase in the risk of bleeding. However, none of the trials was large enough to establish conclusively the efficacy or safety of SK relative to that of anticoagulant therapy.
Recently there has been increased interest in the clinical use of thrombolytic agents, due primarily to the impressive clinical results of thrombolysis in patients with acute myocardial infarctionl1-l3 and to the development of recombinant tissue-type plasminogen activator (rt-PA), which appears to be more effective than SK in lysing coronary a r t e r y t h r~m b i .~~.~~ We therefore performed a double-blind randomized trial in patients with acute proximal DVT and tested two different dosage regimens of rt-PA to determine if thrombolysis can be achieved without producing fibrinogenolysis. In addition, we performed long-term follow-up on all available patients to determine the relationship between thrombolysis and the development of clinical manifestations of the postphlebitic syndrome. heparin infusion administered at a starting dose of 30,000 U/24 h and adjusted to maintain the activated partial thromboplastin time (AFTT) at 1% to 2 times control.
The study was performed in two phases. In phase 1.24 patients were randomly allocated to treatment with two-chain rt-PA, 0.5 m&g infused IV over 4 h, or an identical-appearing placebo. In ohase 11.59 mtients were randomlv allocated to one-chain rt-PA. Heparin was continued during the study drug infusion, then continued for seven to ten days, and followed by oral anticoagulant therapy with warfarin, the dose of which was adjusted to maintain the International Normalized Ratio (INR) at 2.0 to 3.0. Warfarin was continued for three months.
Blood was collected before and after the rt-PA infusion to determine levels of plasma fibrinogen, a,-antiplasmin, and fibrin(ogen) degradation products (FDPs). In addition, A m , thrombin clotting time, and prothrombin times were assayed. The blood was centrifuged at 1,600 g for 15 min at room temperahue, divided into aliquots, and frozen at -70°C for batch assay.
Outcome Aa. ¶esSmt?nts THROMBOLYSIS. The effectiveness of the treatment regimens in producing thrombolysis was assessed with repeat venography at 24 to 48 h after randomization. The venograms were assessed to determine the number of patients in each group who showed a clinically important improvement, defined as thrombolysis of 50 percent or more from baseline, which was the primary outcome measure (Fig 1) . The venograms were interpreted by an independent panel without knowledge of the clinical findings or the treatment group to which any patient had been assigned.
HEMORRHAGE. Each patient was carefully assessed for symp toms and signs of bleeding over the initial 24 h of treatment, and then daily. Bleeding was classified as major if it was clinkally overt and assaciated with a fall in hemoglobin of 2 gdl or more, if it led to a transfusion of two or more units of blood. or if it was retroperitoneal, intracranial, intraocular, or intra-arti:cular. Bleeding was defined as minor if it was clinically overt but did not meet the other criteria for major bleeding.
LONG-TERM FOLLOW-UP. Patients were seen two to three years post treatment for follow-up and evaluated by an investigator blinded to the original treatment regimens. Patients who complained of persistent (greater than one month's duration) pain and swelling of the legs and who had evidence of reflux on Doppler ultrasonography were considered to have the postphlebitic syndrome.
Rztient Pbpulatia
Of the 24 patients in phase I of the study, 12 received rt-PA and 12 received placebo. Fifty-nine patients were recruited to phase 11; 29 received rt-PA and 30 received placebo. fusion value, a fall in a2-antiplasmin to almost undetectable levels, and a fourfold increase in the serum in Tables 1 and 2 . In phase I, of the 12 patients who received 0.5 mgkg of rt-PA plus heparin over 4 h, greater than 50 percent lysis of thrombus was achieved in seven (58 percent). Of the 12 patients who received placebo plus heparin, none had greater than 50 percent lysis. The between-group difference in the proportion of patients who had greater than 50 percent lysis was statistically significant (p = 0.002). In phase 11, of the 28 patients who received rt-PA, 0.5 mgkg infused over 8 h, repeated in 24 h, and who underwent followup venography, greater than 50 percent lysis was achieved in six (21 percent), compared with two (7 percent) of the 30 patients who received placebo plus heparin. The between-group difference in the proportion of patients who had greater than 50 percent lysis favored rt-PA but was not statistically significant (p = 0.11). For phases I and I1 combined, the regimen of 0.5 mgkg of rt-PA appeared to cause more lysis than heparin, but the difference in effectiveness was not quite statistically significant (p = 0.09).
Outcome Assessments
HEMORRHAGE. TWO patients who received 0.5 FDP concentration (Table 3 ). In contrast, in the patients who received rt-PA, 0.5 mgkg over 8 h, there was an 11 percent reduction in mean plasma fibrinogen concentration, a 36 percent reduction in mean a,-antiplasmin levels, and only a moderate increase in serum FDP concentration (Table 4) .
LONG-TERM FOLLOW-UP.
Long-term follow-up was possible in 46 patients; of the other 37 patients, 22 had died and 15 were not readily available for follow-up. Of these 46 patients, seven received heparin plus rt-PA, 0.5 mgkg over 4 h; 20 received heparin plus rt-PA, 0.5 mgkg over 8 h; and 19 received heparin and placebo. Greater than 50 percent lysis was achieved in 12 patients: in five with 0.5 mgkg rt-PA infused over 4 h; in five with 0.5 mgkg rt-PA infused over 8 h, repeated once, and in two with placebo. Three (25 percent) of the 12 patients in whom greater than 50 percent lysis was achieved had symptoms of the postphlebitic syndrome, compared with 19 (56 percent) of 34 in whom less than 50 percent or no lysis was achieved (NS, p = 0.07). In this study, two-chain rt-PA administered over 4 h produced lysis of proximal DVT more often than heparin. The rate of lysis achieved at the higher concentration of rt-PA administered over 4 h is similar to that reported in previous studies using SK administered over 48 to 72 h.1° Because thrombolysis with this rt-PA regimen was associated with a sign&cant fall in plasma fibrinogen concentration, we decided to perform the second phase using a lower concentration but a greater total dose to determine whether effective thrombolysis could be achieved with rt-PA without inducing a systemic fibrinolytic state. Although the regimen used in the second phase produced only a slight fall in fibrinogen, induced thrombolysis was not significantly better than with placebo. Thus, in patients with DVT clinically important thrombolysis with rt-PA may require a dosage regimen that produces a systemic lytic state. The mean dose of rt-PA used in this study was only 40 percent of that used in acute myocardial infarction, where a high rate of coronary thrombolysis occurred with a dose of 100 mg rt-PA given over 3 to 4 h.'l,'2 It is possible that greater thrombolysis of DVT might be achieved with this dose.
In this study, the overall prevalence of the postphlebitic syndrome was 48 percent at three year followup. The data suggest, based on a nonsignificant trend (p =0.07), that the incidence of the postphlebitic syndrome is lower in patients in whom greater than 50 percent lysis is achieved, an observation consistent with reports from other small studies of thrombolysis with SK.1° However, a large-scale clinical trial with a higher dose of rt-PA is required to answer the major remaining question in the treatment of DVT: Does effective thrombolysis reduce the frequency of the postphlebitic syndrome?
